The hallmarks of cancer, first introduced by Hanahan and Weinberg in 2000 and updated in 2011 and in 2022, summarize the core processes that drive the stepwise development of tumors. This framework has proven highly effective for interpreting the vast…
Brain tumors are the most common solid tumors in children. Despite recent advancements in cancer survival, the prognosis for high-grade pediatric brain tumors remains poor, with treatments resulting in severe long-term side effects. Over the last deca…
RAS mutations are among the most prevalent oncogenic drivers in solid tumors and are consistently associated with suboptimal responses to radiation therapy (RT). Within this family, KRAS is the dominant isoform and a central regulator of tumor stress …
The advent of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape of several malignancies, but durable clinical benefits are only observed in a subset of patients. Primary and acquired resistance to immunotherapy, largely drive…
Cancer immunotherapy, particularly immune checkpoint blockade (ICB), has represented a major advancement for the treatment of various cancers. Though ICB has been an effective tool in the clinical management of patients, a significant subset of indivi…
Ovarian cancer (OC) remains one of the deadliest gynecologic malignancies, and, despite the presence of tumor-infiltrating lymphocytes (TILs) in nearly half of cases, immune checkpoint inhibitors have shown only modest clinical benefit. These observat…
T cell receptors (TCRs) are central to adaptive immunity, yet their vast sequence and structural diversity present a significant challenge to fully understand immune responses. The application of high-throughput sequencing technologies, including bulk…
Natural killer (NK) cells are critical effectors of antitumor immunity, however their cytotoxic function is frequently impaired within the tumor microenvironment (TME). Tumor-associated macrophages (TAMs), the most abundant immune stromal population i…
Cutaneous squamous cell carcinoma (CSCC) is a highly prevalent malignancy with rising incidence, particularly among elderly and immunosuppressed individuals. Although most early-stage cases are cured with surgery, a relevant minority present with high…
Despite the success of immunotherapy, chemotherapy remains the backbone of front-line therapy for most patients with cancer. Immune checkpoint inhibitors, T cell engagers, and adoptive cell therapies have traditionally been relegated to second-line or…
